SonoThera Raises $125 Million for Ultrasound-Delivered Genetic Medicines
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
Archive
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
